ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Nov 19, 2017
Dividend Increases/Decreases for the Week Ending November 17
Let's take a look at companies raising/lowering their dividends this week.
Nov 17, 2017
How Have Our Best “Dividend Growth Ideas” Performed During 2017?
We wrote recently about how well the top-weighted ideas in the Best Ideas Newsletter portfolio have performed during 2017, but what about the top-weighted ideas in the other newsletter portfolio, the Dividend Growth Newsletter portfolio? How have they performed during 2017? Please tell us you know how well the top-weighted ideas have been performing.
Nov 17, 2017
Celgene Implodes
The pharma/biotech industry operates in a boom-bust environment where the market cap of a company can post a meteoric rise or suffer a precipitous fall based on the data published from recently completed clinical trials. The industry remains one of the most innovative fields, but the quest for new products leads to constant disruption and a subsequent spike in volatility. Of late, the volatility pendulum for Celgene has swung in favor of the bears with the company posting a costly phase 3 failure.
Nov 16, 2017
Cisco’s Shares Are Surging!
Image Source: Cisco. We received some fantastic news from newsletter portfolio idea Cisco. Shares are surging! Please tell me you knew that Cisco was one of our favorite ideas.
Nov 15, 2017
Buffalo Wild Wings Should Go Private and Hasbro Should Buy Mattel…But at the Right Price
Image Source: Hasbro. There is a lot happening across the M&A landscape as of late. Buffalo Wild Wings has reportedly received a go-private offer, while speculation is swirling that Hasbro is looking to gobble up Mattel. We like the prospects of both scenarios. However, price will always matter. Buffalo Wild Wings should hold out for the very best offer, while Hasbro should be very careful not to overpay for assets that may be past their prime.
Nov 14, 2017
How Have Our “Best Ideas” Performed During 2017?
The top-weighted ideas are getting the job done, while we avoided one of the biggest missteps in all of 2017. We’ve had better years, but 2017 was still a great one.
Nov 14, 2017
GE Takes the Plunge, Halves Dividend
There may have been little surprise across the market when GE halved its dividend in its investor update November 13, but shares are selling off after management issued weaker-than-expected EPS guidance for 2018.
Nov 13, 2017
A Guide to Using Valuentum's Stock Reports
There is no better value in investment research and analysis. Period. Within the individual premium plan, we offer two newsletters (the Best Ideas Newsletter, Dividend Growth Newsletter), delivered by email. On the website, we provide hundreds of stock and dividend reports, proprietary metrics such as the Dividend Cushion ratio, fair value estimates, Valuentum Buying Index ratings, commentary and analysis, weekly screens, plus access to the Valuentum team and much more. As a member, learn more about Valuentum's stock reports by downloading the guide here (pdf). Thank you!
Nov 11, 2017
4 Burning Questions About Gilead Sciences
Image Source: Gilead. We were pleased with the jump in shares of Gilead Sciences following its recent addition to the newsletter portfolios. The equity has given back some of those gains more recently as questions have resurfaced on the vitality of the enterprise. In this article, we work through the top 4 questions for readers to consider in evaluating Gilead Sciences.
Nov 10, 2017
Could Sally Beauty Become Amazon’s “Whole Foods” Foray into Beauty Supply?
Image Source: Sally Beauty.  “The Amazon Effect” on traditional retail is not a new development, but there are some pockets of retail that were believed to be impenetrable by the e-commerce giant. We’re beginning to see that such a notion may have been nothing short of wishful thinking.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.